Get started
Author

Thilo Zander

Observed names: T Zander, T. Zander, THILO ZANDER, Zander, T, Zander, Thilo, Zander, Thilo J.
ORCID: 0000-0003-3691-7497
Observed ORCID: 0000-0003-3691-7497
OpenAlex ID: A5020563845
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
2020 · Michele Cavo, Francesca Gay, et al. · The Lancet Haematology · 386
PDF
A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
2013 · Oliver Gautschi, Thilo Zander, et al. · Journal of Thoracic Oncology · 101
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
2019 · Emanuele Zucca, Stephanie Rondeau, et al. · Blood · 67
PDF
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
2011 · Silvia Hofer, Katarzyna Elandt, et al. · Acta Oncologica · 45
PDF
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
2021 · Pieter Sonneveld, Meletios A. Dimopoulos, et al. · Journal of Clinical Oncology · 43
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
2016 · Stefanie Gilli, Urban Novak, et al. · Annals of Hematology · 43
PDF
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma
2018 · Christoph Driessen, Rouven Müller, et al. · Blood · 38
Response to Pembrolizumab in a Patient with Relapsing Thymoma
2016 · Thilo Zander, Stefan Aebi, et al. · Journal of Thoracic Oncology · 37
Prognostic factors in Hodgkin's lymphoma
2002 · T. Zander, S. Wiedenmann, et al. · Annals of Oncology · 34
PDF
Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients
2015 · C Kamber, S Zimmerli, et al. · Bone Marrow Transplantation · 25
Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study
2020 · Michele Cavo, Francesca Gay, et al. · Blood · 21
High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients
2019 · Irene Prediletto, Sarah A. Farag, et al. · Bone Marrow Transplantation · 21
Diagnosis and treatment of follicular lymphoma: an update
2018 · Mario Bargetzi, Reto Baumann, et al. · Swiss Medical Weekly · 18
PDF
The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)
2016 · Christoph Driessen, Rouven Müller, et al. · Blood · 18
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10
2014 · Eva Kimby, Giovanni Martinelli, et al. · Blood · 18
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
2018 · Ursina Gössi, Barbara Jeker, et al. · Hematological Oncology · 17
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
2019 · Isabel G. Amsler, Barbara Jeker, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
2020 · A. A. Moccia, S. Aeppli, et al. · Hematological Oncology · 15
Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
2022 · Sarah Farag, Ulrike Bacher, et al. · Bone Marrow Transplantation · 14
PDF
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
2023 · Urban Novak, Martin Fehr, et al. · EClinicalMedicine · 12
PDF
The Clinical Value of Echocardiography and Acoustic Cardiography to Monitor Patients Undergoing Anthracycline Chemotherapy
2012 · Stefan Toggweiler, Yvonne Odermatt, et al. · Clinical Cardiology · 11
PDF
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
2016 · Oliver Gautschi, Sacha I. Rothschild, et al. · Clinical Lung Cancer · 10
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
2015 · Panagiotis Samaras, Mario Bargetzi, et al. · Swiss Medical Weekly · 10
PDF
Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
2022 · Jeanne Bohler, Ulrike Bacher, et al. · Cancers · 9
PDF
Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10
2016 · Eva Kimby, Stephanie Rondeau, et al. · Blood · 9
Works count: 67
Citation count: 1,124
H-index: 16
I10-index: 23
Year
Topic
Type